Cyclin G is a transcriptional target gene of tumor suppressor p53. Recent studies present evidence that cyclin G may play a central role in the p53-Mdm2 autoregulated module, but the precise function of cyclin G remains elusive. Here, we show a negative effect of cyclin G on the stability of p53 and p73. Cyclin G expression resulted in a dramatic decrease of p53 protein levels in response to DNA damage and abrogated irradiationmediated G1 arrest along with an increase of S phase in MCF7 cells containing wild-type p53. In p53-null Saos2 cells, cyclin G inhibited p73 induction in response to genotoxic stress and delayed the camptothecin-mediated cell cycle arrest. Cyclin G interacts with p53 as well as p73, and its binding to p53 or p73 presumably mediates downregulation of p53 and p73. We also found that cyclin G-mediated reduction of p53 but not of p73 is Mdm2-dependent. Moreover, inhibition of cyclin G by small interfering RNA (siRNA) caused the accumulation of p53 and p73 protein levels in response to DNA damage. Therefore, our results imply that cyclin G is transcriptionally activated by p53 or p73, and, in turn, cyclin G negatively regulates the stabilization of p53 family proteins through an unknown mechanism different from ubiquitination or transcriptional control.
Introduction
The p53 tumor suppressor gene plays a crucial role in cancer progression, and it is inactivated in the majority of human tumors. Depending on cell context, wild-type p53 limits cellular proliferation in response to DNA damage and other cellular stresses by inducing cell cycle arrest, apoptosis or senescence (Ko and Prives, 1996; Levine, 1997; Burns and El-Deiry, 1999; Lin et al., 2000; Oda et al., 2000; Vogelstein et al., 2000; Vousden, 2000) . It has been shown that inhibition of cell proliferation by p53 is largely due to its ability to transcriptionally activate genes that directly control cell fate (Ko and Prives, 1996; Polyak et al., 1996; Levine, 1997; Vogelstein et al., 2000) . p53-induced cell cycle arrest is mainly mediated by the p53 target gene p21, an inhibitor of cyclin-dependent kinases (El-Deiry et al., 1993; Bunz et al., 1998) . Bax, IGV-BP3, p53AIPl, DR5, PREP, Pidd and PUMA, which are transcriptional targets of p53 are thought to be mediators of p53-induced apoptosis (Buckbinder et al., 1995; Miyashita and Reed, 1995; Wu et al., 1997; Attardi et al., 2000; Lin et al., 2000; Oda et al., 2000; Nakano and Vousden, 2001) .
Protein level of p53 is normally kept low because of its rapid degradation (Haupt et al., 1997) , but under the various kinds of stresses including DNA damage, hypoxia, serum starvation, and heat, p53 is stabilized and induces several transcriptional targets such as p21, Gadd45, 14-3-3b and Bax to trigger growth arrest or apoptosis, which prevent the accumulation of genomic alterations (Yu et al., 1999) . Mdm2, also a target gene of p53, is well known for binding p53 and regulating protein level of p53 (Haupt et al., 1997) . The stabilization of p53 is considered to be the result of the inhibition of the ability of Mdm2 to bind p53 and to degrade p53 by ubiquitination (Haupt et al., 1997) . On the other hand, the p53-related protein p73 is transcriptionally regulated in response to DNA damage (Chen et al., 2001) , and c-Abl induces the phosphorylation of p73 on tyrosine and threonine residues and enhances the stabilization of p73 (Gong et al., 1999) . It is also known that Mdm2 binds to p73 to repress the transcriptional activity of p73 but does not influence p73 degradation (Zeng et al., 1999) .
Cyclin G, a member of cyclin family, was initially identified as a homologous protein to c-src (Tamura et al., 1993) and subsequently, demonstrated to be one of the target genes of tumor suppressor p53 (Okamoto and Beach, 1994; Zauberman et al., 1995) . Since then, several studies have investigated its p53-dependent roles.
However, the precise function of cyclin G is still obscure. Some recent studies showed that cyclin G enhanced cellular growth (Skotzko et al., 1995; Smith et al., 1997; Shimizu et al., 1998) and suspected that it might work as an oncogenic protein due to cyclin overexpression in human tumor cells (Reimer et al., 1999) . In contrast, others have demonstrated the contribution of cyclin G to G2/M arrest in response to DNA damage (Kimura et al., 2001) or the facilitation of TNF-a-induced apoptosis (Okamoto and Prives, 1999) , which is implicated in tumor suppressive function. Recently, it has been demonstrated that cyclin G recruits phosphatase 2A to regulate Mdm2 by the dephosphorylation of Mdm2 (Okamoto et al., 2002) . Dephosphorylation of Mdm2 may result in the activation of Mdm2 to inhibit p53 function. In fact, in cyclin G (À/À) cells, a decrease in dephosphorylation of Mdm2 and an increase in the protein level of p53 are observed when compared with cyclin G (+/+) cells (Kimura et al., 2001; Okamoto et al., 2002) . These data strongly suggest that cyclin G contributes to p53 regulation (Chen, 2002) . Here, we describe the effect of cyclin G on the regulation of p53 and p73 stability. It was found that cyclin G interacts with p53 as well as p73, and presumably mediates the downregulation of p53 and p73. In addition, cyclin G promoted p73 degradation but did not promote the degradation of p53 in Mdm2-null MEFs, suggesting that cyclin G-mediated repression of p53 is Mdm2-dependent. Blocking endogenous cyclin G expression by siRNA significantly increased levels of endogenous p53 or p73 protein in response to genotoxic stresses. These results provide evidence that cyclin G regulates the stability of p53 through a negative feedback pathway although the mechanism(s) responsible for the cyclin G-mediated degradation of p53 or p73 has not yet been defined.
Results

Effects of cyclin G on protein levels of p53 and p73
To define the physiological role of cyclin G in p53 regulation, we exogenously expressed cyclin G in MCF7 cells by infection of a recombinant adenovirus expressing human cyclin G, then treated the cells with mitomycin C (MMC, 2.5 mg/ml) or g-irradiation (10 Gy). GFP expressing virus was used as control. As shown in Figure 1a , cyclin G expression significantly inhibited the endogenous protein levels of p53 induced in response to DNA damage, while p53 level was increased in the Ad-GFP infected control cells, in response to DNA damage. In addition, the functionality of the cyclin G-mediated p53 repression was demonstrated by decreased levels of p21 and Mdm2, the transcriptional targets of p53 ( Figure 1a ). We also examined the effect of cyclin G on the p53-related protein, p73. Forced expression of cyclin G inhibited p73a induction in response to campthothecin treatment (CPT, 300 nm) in p53-null Saos2 cells, along with a reduced level of p21 ( Figure 1b) . Next we took advantage of MCF7 cell line that contains relatively high endogenous p73a and b expression to determine the negative effect of cyclin G. As predicted, ectopic cyclin G expression lowered p73a and b protein levels ( Figure 1b) . To confirm cyclin G-mediated repression of p53 or p73 expression, p53 or p73 was introduced with or without cyclin G in Saos2 cells using adenoviruses expressing p53, p73 or cyclin G. Consistent with the results obtained from DNA damage treatment, cyclin G caused to reduce levels of exogenous p53 as well as p73 (Figure 1a and b) . These results demonstrated that cyclin G promotes the reduction of p53 or p73 proteins including p73a, p73b and DNp73b under the genotoxic stress conditions. Attenuation of genotoxic stress-induced cell cycle arrest by cyclin G To determine the biological effects of the cyclin Gmediated downregulation of p53 or p73, we examined the effects of cyclin G overexpression in DNA damageinduced cell cycle arrest. For this purpose, we used two cell lines, MCF7 containing wt-p53 and p53-null Saos2 containing wt-p73. First MCF7 cells were infected with Ad-cyclin G or Ad-GFP, then 48 h after postinfection, cells were exposed to g-irradiation (10 Gy) and collected for cell cycle analysis by fluorescence-activated cell sorting (FACS). Exposure of control MCF7 cells, infected with Ad-GFP, to g-irradiation resulted in a marked increase in GO/G1 and G2/M population along with reduced S phase cells (Figure 2a) . However, exposure of cyclin G expressing MCF7 cells to girradiation resulted in a reduced GO/G1 population (from 70 to 51%) as well as increased S and G2/M phase cells (S phase: from 4 to 11%; G2/M: from 25 to 36%). In untreated cells, cyclin G also increased G2/M phase with slight reduction of G1 population as previously described (Kimura et al., 2001) . In addition, Saos2 cells were infected with Ad-cyclin G or Ad-GFP, treated with 300 nm of CPT, and collected 12 h after CPT treatment. CPT-treated Saos2 cells were preferentially arrested at GO/G1, whereas cyclin G-expressing cells abrogated the CPT-mediated cell cycle arrest and resulted in an increased S phase (Figure 2b ). These results imply that the impairment of p53 or p73 function by cyclin G leads to the delay of genotoxic stress-mediated cell cycle arrest.
Mdm2 is involved in cyclin G-mediated p53 repression but not in p73 repression
Previous studies demonstrated that cyclin G binds to Mdm2 and stimulates dephosphorylation of Mdm2 by PP2A and thereby, regulates both Mdm2 and p53 (Okamoto et al., 2002) . Other reports also found that cyclin G interacted directly with Mdm2 and promoted the formation of the ARF/Mdm2 complex in response to DNA damage (Kimura and Nojima, 2002) . However, it is not yet clear whether Mdm2 is directly involved in the biological function of cyclin G (Chen, 2002) . Therefore, we compared the negative effects of cyclin G on p53 and p73 stability in Mdm2-deficient mouse embryonic fibroblasts (MEFs) with that in Mdm2-intact MEFs. Figure 3a shows that cyclin G can reduce p53 protein levels in Mdm2-intact MEFs (Mdm2+/+). However, p53 levels remained unchanged when cyclin G and p53 were coexpressed in the Mdm2-deficient MEFs. Cyclin G was able to reduce p73 protein levels but not p53 levels in both the Mdm2-null and the Mdm2-intact MEFs. In addition, we assessed the negative effect of cyclin G on a mutant p53 containing a mutation in Mdm2-binding site (Bean and Stark, 2002) . Saos-2 cells were co-transfected with a Mdm2-binding site mutant p53 and cyclin G and determined levels of p53 by Western blotting. As shown in Figure 3b , expression levels of exogenous p53 containing a Mdm2-binding site mutant remained unchanged by cyclin G as seen in Mdm2-null cells. It should be noted that the effect of cyclin G on p73 levels in response to cyclin G was much more effective than that of p53. These results suggest that Mdm2 is involved in cyclin G-mediated downregulation of p53 but not in p73.
Association of cyclin G with p53 or p73
Recent reports showed that cyclin G recruits PP2A in order to modulate the phosphorylation of Mdm2, thereby regulating both Mdm2 and p53 (Okamoto et al., 2002) . Moreover, Mdm2 phosphorylation and p53 levels are increased in cyclin G-null MEFs (Okamoto et al., 2002) . To evaluate the potential associations between cyclin G and p53 or p73, we (a) Cyclin G-mediated reduction of p53 in response to DNA-damaging agents, g-irradiation and MMC. MCF7 cells were infected with Ad-GFP or Ad-cyclin G then exposed to g-irradiation (10 Gy) or MMC (2.5 mg/ml). Cells were harvested at the indicated times, and Western blotting was performed using antibodies against p53, cyclin G, mdm2, p21 and b-actin antibodies. Right panel: Effect of cyclin G on exogenous p53. Saos2 cells were infected with both Ad-p53 and Ad-cyclin G or Ad-p53 alone. (b) Cyclin G-mediated reduction of p73 isoforms in response to genotoxic stress in p53-null Saos2 cells. Saos2 cells were infected with Ad-GFP or Ad-cyclin G then treated with CPT (300 nm). Cells were harvested at the indicated times and analysed for the expression of the designated proteins by Western blotting using antibodies against p73, cyclin G, p21 and b-actin. Effects of cyclin G were examined on endogenous p73 proteins (p73a and b). MCF7 cells were infected with Ad-GFP or Ad-cyclin G at 100 moi then collected 48 h after infection for immunoblotting against p73a and b, cyclin G and b-actin. Effect of cyclin G was examined on exogenous p73 levels. Saos2 cells were infected with Ad-HA-73a and Ad-cyclin G or Ad-HA-p73a alone. Cells were harvested 48 h after infection and analysed for the levels of p73 proteins by immunoblotting using antibodies against HA, cyclin G, p21 and b-actin. Saos-2 cells were also cotransfected with the plasmid expressing Flag-cyclin G and the plasmid with HA-p73b or HA-nNp73b. Cells were harvested and analysed for the levels of p73 proteins by Western blotting using antibodies against HA, Flag and b-actin Cyclin G-mediated modulation of p53 and p73
T Ohtsuka et al performed immunoprecipitation-Western analysis of U2OS cells. Cells were transfected with Flag-cyclin G and exposed to a DNA-damaging agent, MMC (2.5 mg/ ml), for 12 h to activate p53 or cotransfected with HAp73 expression vector. Proteins were coimmunoprecipitated with the anti-p53 or HA-epitope (for p73 detection) antibodies and anti-Flag epitope antibodies for cyclin G detection, respectively, followed by Western blotting with Flag antibody and the monoclonal p53 or HA-epitope antibodies. As shown in Figure 4 , p53 or p73 proteins were detected in anti-Flag coimmunoprecipitates and exogenous cyclin G was also detected in anti-p53 and anti-HA (p73) immunoprecipitates. These results indicate that there is an association of cyclin G Ad-cyclin G then exposed to 300 nm of CPT to induce p73. Cells were collected after 12 h CPT treatment, and the cell cycle distribution was analysed by FACS Cyclin G-mediated modulation of p53 and p73 T Ohtsuka et al with p53 and p73, although the functional significance of these interactions in the cyclin G-mediated downregulation of p53 and p73 proteins needs to be investigated.
Cyclin G-mediated downregulation ofp53 and p73 is not controlled by ubiquitination or transcriptional regulation
We next examined whether cyclin G regulates the degradations of p53 or p73 via any specific mechanism such as transcriptional regulation or ubiquitination. The mRNA levels of p53 were examined in cyclin G overexpressing cells. U2OS cells were transfected with Flag-cyclin G or a mock vector, then exposed to MMC for 24 h and harvested cells for RNA isolation. Figure 5a showed that cyclin G decreased the protein level of p53, but there was no significant change in mRNA levels of p53 suggesting that the decrease of p53 levels by cyclin G involves the stabilization of the protein. Therefore, we next investigated the effect of cyclin G expression on p53 stability. U2OS cells were transfected with Flag-cyclin G expression or mock vector and exposed to MMC. Cells were then treated with cycloheximide (CHX) to inhibit de novo p53 synthesis, and the steady-state levels of p53 were determined at the indicated times. In control cells, p53 protein level remained stable 4 h after CHX treatment; however, the half-life of the p53 protein in cyclin G-transfected cells was less than 4 h (Figure 5b ). These data suggest that cyclin G causes destabilization of the p53 protein.
Since it is well documented that the stability of p53 protein is regulated by a ubiquitination process, we tried to determine if the destabilization of p53 by cyclin G was due to the increased ubiquitination of p53 in vivo. MCF7 cells were infected with Ad-cyclin G or Ad-GFP and were either treated or untreated with MMC then examined by immunoprecipitation-Western blot analysis using antibodies specific for p53. All cells were pretreated with a proteasome inhibitor, N-acetylleu-leu-norleu-al (LLNL), to visualize a ladder of ubiquitinated p53 protein bands 12 h prior to harvesting the cells. Then, cells were immunoprecipitated with FL393 anti-p53 polyclonal antibody and analysed by Western blotting with DO-1 anti-p53 monoclonal antibody. If cyclin G promoted an increased ubiquitination As a control, mouse IgG was used for IP experiment was added Cyclin G-mediated modulation of p53 and p73 T Ohtsuka et al of p53 protein, we expected a decrease in steady-state p53 levels as well as an increase in ladder bands of the ubiquitinated p53 proteins (Ub-p53). However, as shown in Figure 5c , although steady-state p53 protein level was reduced by cyclin G, endogenous Ub-p53 level did not increase in MCF7 cells. The same experiments were performed in p53-null Saos2 cells with the addition of exogenous p53 (Figure 5c ). The results were similar to that of MCF7, showing that cyclin G did not increase exogenous Ub-p53 although ectopic p53 was decreased in response to cyclin G overexpression. Furthermore, we also investigated the role of cyclin G in regulating p73 via transcriptional downregulation. Saos2 cells were infected with Ad-cyclin G or Ad-GFP, then treated with 300 nm of CPT. As shown in Figure 6a , the level of p73 mRNA consistently increased in response to CPT treatment, regardless, of cyclin G overexpression. Instead, the level of p21 mRNA, a target gene of p73, was repressed in cyclin G overexpressing cells, and this reduction is presumably due to the cyclin G-mediated p73 protein reduction. Since cyclin G had no observable effect on p73 mRNA levels, we deduce that the reduction of p73 levels by cyclin G involves the stabilization of the protein. The stability of p73 protein was therefore examined in U2OS cells that were cotransfected with either HA-p73 with Flag-cyclin G or HA-p73 with mock vectors, then treated with CHX to inhibit de novo p73 synthesis. The steady-state levels of p73 were determined at the indicated times (Figure 6b ). Under these conditions, the half-life of p73 in control cells was less than 4 h but was less than 2 h in cyclin G overexpressing cells, Figure 5 Cyclin G causes p53 destabilization. (a) Cyclin G does not reduce p53 mRNA levels. U2OS cells were transfected with Flagcyclin G expression vector or mock vector and exposed to MMC (2.5 mg/ml) for 24 h. Cells were harvested for RNA and total proteins. Protein levels were analysed by immunoblotting using antibodies against p53, cyclin G, Mdm2 and b-actin. mRNA levels of p53 were evaluated by Northern blotting with a p53 probe. Loading variations were monitored by rehybridizing the same blot with a 36B4 probe. (b) Effect of cyclin G on p53 stability. U2OS cells were transfected with Flag-cyclin G expression or mock vector and treated with MMC. Cells were then chased with CHX (20 mg/ml), to inhibit de novo p53 synthesis. The steady-state levels of the p53 protein were determined at the indicated times (0, 1,2 and 4 h) by Western blot analysis with the p53 specific antibodies. (c) Ubiquitination of p53 by cyclin G. Western blot analysis of immunoprecipitates with anti-p53 polyclonal antibody from the cells infected with Ad-cyclin G or Ad-GFP (control) with or without MMC treatment. MCF7 cells were pretreated with 20 nm of LLNL for 12 h then analysed by immunoprecipitation-Western blotting with anti-p53 monoclonal antibody (Ab-6, Oncogene). Saos2 cells were coinfected with both Ad-p53 and Ad-cyclin G and were subjected to immunoprecipitation-Western blot analysis using p53 antibodies. Note that expressing cyclin G did not increase Ub-p53 in MCF7 cells (endogenous p53) or in Saos2 cells (exogenous p53) implicating the role of cyclin G in the destabilization of the p73 protein.
To determine whether the destabilization of p73 by cyclin G was due to the ubiquitination of p73 in vivo, Saos2 cells were coinfected with Ad-HA-p73 and Adcyclin G, then treated with LLNL. Cell lysates were immunoprecipitated with anti-HA monoclonal antibody, then immunoblotted with anti-HA monoclonal antibodies. The anti-HA antibody detected a ladder of p73 specific bands from both cyclin G overexpressing and control Saos2 cells, but cyclin G did not increase the ubiquitination of p73 (Figure 6c ). These results demonstrate that cyclin G causes a destabilization of p53 and p73 proteins but not via the ubiquitin-proteolytic pathway.
Inhibition of cyclin G expression results in the accumulation of p53 and p73
We assessed the effect of the inhibition of cyclin G expression on the status of p53 and p73 proteins. U2OS and Saos2 cells were transfected with small-interfering RNA (siRNA) against cyclin G or control siRNA (siRNA against luciferase). After 24 h, cells were DNA damaged (U2OS: MMC; and Saos2: CPT) for 24 h to activate p53 and p73, respectively. siRNA oligo against cyclin G significantly decreased the protein level of cyclin G and resulted in the accumulation of p53 protein levels in U2OS cells (Figure 7a ) and p73 protein levels in Saos2 cells (Figure 7b ).
Discussion
We report here the downregulation of p53 and p73 by cyclin G in response to genotoxic stresses, which induce p53 or p73. Furthermore, we show that the cyclin Gmediated downregulation of p53 is abrogated in Mdm2-null MEF cells. Cyclin G is transcriptionally activated by p53 or p73 (Okamoto and Beach, 1994; Zauberman et al., 1995; Di Como et al., 1999) , while our present data provide evidence that cyclin G negatively regulates Figure 6 Effect of cyclin G overexpression on the level and ubiquitination of p73. (a) Cyclin G does not reduce p73 mRNA levels. Saos2 cells were infected with Ad-GFP or Ad-cyclin G and treated with CPT (300 nm) for up to 24 h. Cells were harvested for RNA at the indicated times. mRNA levels of p73, p21 and 36B4 (loading control) were analysed by Northern blotting using the indicated probes. (b) Effect of cyclin G on p73 stability. U2OS cells were cotransfected with HA-p73 and Flag-cyclin G, or HA-p73 and mock vectors. At 24 h after transfection, cells were treated with CHX (20 mg/ml) to inhibit de novo p73 synthesis, and the levels of p73a were determined at the indicated times by Western blotting using anti-HA antibody. (c) Ubiquitination of p73 by cyclin G. Saos2 cells were coinfected with either Ad-p73a and Ad-cyclin G, or Ad-p73a and Ad-GFP. At 48 h after infection, cells pretreated with 20 nm of LLNL for 12 h were immunoprecipitated with anti-HA monoclonal antibody and analysed by Western blot analysis with anti-HA monoclonal antibodies Cyclin G-mediated modulation of p53 and p73
T Ohtsuka et al the stabilization of p53 family proteins. Cyclin G belongs to the members of cyclin family and contains a well conserved cyclin box but lacks a PEST sequence or destruction box (Tamura et al., 1993) . Compared to the other members of cyclin family, the role of cyclin G in cell cycle checkpoints is not well elucidated. In addition, although cyclin G was identified as a direct p53 target gene, its function in the p53 pathway has also been elusive (Okamoto and Beach, 1994; Zauberman et al., 1995) . A number of studies have shown that cyclin G has growth-promoting functions and is highly expressed in several cancers (Skotzko et al., 1995; Smith et al., 1997; Shimizu et al., 1998; Reimer et al., 1999) . It has been reported that cyclin G is tightly regulated in normal cells, peaking at the S and G2/M phases of cell cycle, and this cell-cycle-dependent expression was absent in cancer cells (Reimer et al., 1999) . Several reports have also demonstrated the effect of cyclin G on cell cycle progression in response to DNA-damaging agent in cell lines containing wt p53. Cyclin G overexpressing cells tend to be more sensitive to cisplatin cytotoxicity than the parental cells (Smith et al., 1997) . Antisense inhibition of cyclin G resulted in a marked reduction in G2/M arrest in rat fibroblast cells in response to doxorubicin treatment (Shimizu et al., 1998) , while ectopic overexpression of cyclin G in the human RKO cancer cell line accelerated cell growth (Smith et al., 1997) . Another group reported, however, that cyclin G contributes to G2/M arrest of cells (Kimura et al., 2001) , but others showed that cyclin G expression enhanced apoptotic cell death induced by TNF-a in NIH3T3 fibroblasts (Okamoto and Prives, 1999) . At the moment, the existing data for the function of cyclin G in growth regulation remain controversial. A recent report demonstrated that cyclin GÀ/À mice were more sensitive to DNA-damaging agents including g-irradiation than wild-type mice, and FACS analysis revealed that the G2/M phase in cyclin G null-MEFs after irradiation was 50% less than G2/M arrest in cyclin G1+/+ MEFs after damage (Kimura et al., 2001 ). While no difference was detected in the induction of apoptosis between mouse embryo fibroblasts (MEFs) derived from cyclin G+/+ and cyclin GÀ/À mice following irradiation, cyclin GÀ/À MEFs proliferated more slowly and reached lower cell densities in culture dishes than cyclin G+/+ MEFs (Kimura et al., 2001 ). Analysis of cell survival showed that cyclin GÀ/À MEFs were more sensitive than cyclin G+/+ MEFs in response to g-or UV-radiation. These results are somewhat consistent with the growth-promoting role of cyclin G and suggest a role for cyclin G in G2/M arrest in response to DNA damage.
It is well established that Mdm2 negatively regulates p53 through the ubiquitin-proteasome pathway (Haupt et al., 1997) . There is a consensus that Mdm2 seems to play a key role in maintaining a low protein p53 level in the normal cell, and genotoxic stress inhibits this Mdm2 function and induces the stabilization of p53 (Haupt et al., 1997) . However, the mechanism of p53 stabilization in response to stress is still controversial. Previous reports showed that ubiquitination of p53 was affected differently by different types of DNA damage (Maki and Howley, 1997; Inoue et al., 2001) . UV irradiation and alkylating agents stabilize p53 by inhibiting p53 ubiquitination; however, g-irradiation, etoposide and actinomycin D do not affect on ubiquitination of p53 but increase the stability of p53. Thus, stabilization of p53 may be regulated by not only the ubiquitin-proteasome pathway but also through other unknown mechanisms. A recent report indicates that cyclin G does not directly bind to p53, but instead, binds to p53 via Mdm2 (Kimura and Nojima, 2002; Okamoto et al., 2002) . These studies also demonstrate that cyclin G recruits PP2A to dephosphorylate Mdm2, which results in the activation of Mdm2 function (Okamoto et al., 2002) , raising the important question that cyclin G has an impact on the activity of Mdm2 in regard to p53. Thus, Mdm2 might play an important role in cyclin G-mediated p53 downregulation. However, our results demonstrate that ubiquitination is not a main pathway in the functional interaction of cyclin G and p53. Further investigation is necessary to clarify the role of cyclin G in regulating the stability of p53 family proteins.
We observed that the forced overexpression of cyclin G enhanced G2/M arrest following g-irradiation and Cyclin G-mediated modulation of p53 and p73 T Ohtsuka et al resulted in the reduction of GO/G1 population along with an increased S phase in MCF7 cells with intact p53. The effect that a reduction of endogenous p53 level in response to cellular stress has on the cell phenotype may vary depending on the type of DNA damage. In fact, our findings are consistent with previous reports which show that in response to genotoxic stresses, cyclin G shifts cells toward G2/M arrest (Shimizu et al., 1998; Kimura et al., 2001) or growth stimulation (Smith et al., 1997; Kimura et al., 2001) . In Saos2 cells, following CPT treatment, the forced expression of cyclin G significantly increased S phase cells along with the reduction of GO/ G1 population but resulted in no specific change in the G2/M phase, implying that there is a difference in the functional interactions between p53-cyclin G and p73-cyclin G. Saos2 cell line is p53-null and induces p73 in response to CPT treatment (Chen et al., 2001) . siRNA against cyclin G was able to inhibit cyclin G expression and caused the accumulation of p53 and p73 protein levels. These data as well as cycloheximide chase experiments strongly support the role of cyclin G in the stability of p53 family proteins.
In this report, we have not established the mechanism(s) that regulate the cyclin G-mediated downregulation of p53 and p73. However, our results invite consideration that cyclin G is a negative regulator of p53 family proteins by promoting protein degradation and that cyclin G functions through a negative feedback regulation of the p53-Mdm2 autoregulatory module. Identification of additional components in this network should provide important insight into the control of action of cyclin G in p53 and p73 regulation.
Materials and methods
Cell lines and cell culture conditions MCF7, U2OS, Saos2, and Mdm2-intact and Mdm2-null MEFs were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (Gibco), 100 U/ml of penicillin and 100 mg/ml of streptomycin at 371C. For drug treatment, cells were exposed to mitomycin C (MMC) (Sigma) at concentration of 2.5 mg/ml or camptothecin (CPT) (Sigma) at 300 nm for 12-24 h. Cells were treated with g-irradiation at a dose of 10 Gy. Cycloheximide (CHX) (Sigma) was added to a final concentration of 20 mg/ml to determine the half-life of the protein. For the analysis for p53 and p73 ubiquitinations, cells were treated for 12 h with 20 nm of LLNL (Sigma), a proteasome inhibitor.
Cell transfections and adenovirus infections
The full-length cDNA of cyclin G was subcloned into pcDNA3, and a Flag-tag was added to the N-terminus of cyclin G by PCR then sequenced to confirm the open-reading frame. Cells were transfected with Lipofectamine 2000 (Invitrogen), and the total volume of plasmids were kept constant with an empty vector. Adenovirus expressing cyclin G was generated as previously reported . Briefly, the full-length cDNA of cyclin G was subcloned into pAdTrack shuttle vector and recombination was performed in BJ5180 containing the pAdEasy-1 vector. Recombinant virus was isolated, amplified and analysed for protein expression. Cells were infected with cyclin G (Ad-cyclin G), p53 (Ad-p53), and GFP (Ad-GFP) at a multiplicity of infection (moi) of 100. HA-tagged p73a plasmid (pcDNA3) and adenovirus (Ad-p73a) were generous gifts from M Kaghad and T Ouchi, respectively.
Western blot analysis and immunoprecipitation
Cells were transiently transfected or infected with cyclin G, p53, p73 and/or control constructs and lysed in lysis buffer (20 mm Tris [pH 7.4], 5 mm EDTA, 10 mm Na 4 P 2 O 7 , 100 mm NaF, 2 mm Na 3 VO 4 , 1% NP-40, 1 mm PMSF, 10 mg/ml aprotinin, and 10 mg/ml leupeptin). An equal amount of total cellular proteins per sample was run on a SDS-PAGE and transferred to a nitrocellulose membrane (Invitrogen). Immunoprecipitation was performed using 500 mg of cell extracts using p53 antibodies (Ab-1 monoclonal, Oncogene or FL393 polyclonal, Santa Cruz), anti-Flag monoclonal (M2, Sigma), and anti-HA monoclonal (11, Covance) antibodies, mixed and incubated at 41C for 3 h. Anti-rabbit mouse monoclonal IgG (Sigma) was used as control. In all 20 ml of protein A-(Sigma) or G-(Oncogene) conjugated agarose beads were then added, and the beads were washed and subjected to SDS-PAGE followed by immunoblotting. Antibodies for immunoblotting experiments include DO-1 anti-p53 (Ab-6, Oncogene), antip21 (Ab-1, Oncogene), anti-Mdm2 (Ab-2, Oncogene), antiFlag (M2, Sigma), anti-cyclin G (polyclonal Ab, Upstate), anti-HA (11, Covance), anti-p73 (Ab-4, ER-13+ER-15+GC-15, Lab Vision), anti-ubiquitin (Chemicon) and anti-b-actin (AC 15, Sigma) antibodies. Bands were detected using the ECL chemiluminescence detection method (Amersham).
FACS analysis
Cells were washed with PBS and collected by centrifugation into polystyrene tubes. Ice-cold 80% ethanol was then added dropwise over the pellets with periodical voltexing to mix cells. After fixation, propidium iodine was added at a concentration of 50 mg/ml in PBS, and samples were analysed by flow cytometry (Becton Dickinson FACScan). Data were processed with VERITY ModFit ver. 5.2 MS-Windows software for DNA distribution analysis.
Northern blot analysis
Total RNA was extracted, denatured, electrophoresed through a 1 % agarose-formaldehyde gel and transferred on to a nylon membrane (Bio-Rad). Hybridization was performed with 32 P-labeled probes prepared by the randomly primed DNA-labeling method.
siRNA experiment
The following RNA oligonucleotides were purchased from Dharmacon; 5 0 -AAGUCAGUUGCCAAUGGGACAdTdT-3 0 (cyclin G nucleotides 340-360). Cells were transfected with oligofectamine (Invitrogen) by the manufacturer's protocol in the presence of 40 nmol of small interfering RNA (siRNA) oligonucleotides. Cells were collected 48 h after transfection.
